PTYLTD
    • Insights
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Insights

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic

By Topic

National Australia Bank (ASX: NAB)

National Australia Bank (ASX: NAB): $1.55B Credit Charge Puts Business Lending Strength to the Test

Nov 5, 2026
Proactive Equities Team

National Australia Bank (ASX: NAB) reported lower FY26 cash earnings as a software accounting change and higher credit impairment charges hit profit, while business lending grew strongly, the 85 cent final dividend held steady and job cuts target costs.

REA Group (ASX: REA)

REA Group (ASX: REA): Pricing Strength Drives Quarterly Revenue to $450m Despite Softening Listings

Nov 5, 2026
Proactive Equities Team

REA Group (ASX: REA) lifted first-quarter revenue 11% to $450m as higher pricing offset weaker property listings, kept its full-year outlook unchanged, and flagged tax changes and borrowing costs as the main drags on buyer demand.

Kalgoorlie Gold Mining (ASX: KAL)

Kalgoorlie Gold Mining (ASX: KAL): Lighthorse Drill Results Could Expand 214,300oz Gold Resource

Nov 5, 2026
Proactive Equities Team

Kalgoorlie Gold Mining (ASX: KAL) reported its highest-grade gold yet at Lighthorse, extended mineralisation beyond its Kirgella Gift–Providence resource, secured a heritage agreement and raised fresh capital, as shareholders prepare to vote at the November annual meeting.

Jameson Resources (ASX: JAL)

Jameson Resources (ASX: JAL): A$9.73M Capital Raise Advances Crown Mountain Toward Development

Nov 4, 2026
Proactive Equities Team

Jameson Resources (ASX: JAL) has secured A$9.73 million through a capital raise to advance its Crown Mountain coking coal project, support environmental approvals, strengthen commercial discussions with steelmakers, and progress toward development.

Noxopharm (ASX: NOX)

Noxopharm (ASX: NOX): $1.5M Raise Funds Lupus Skin Study and Cancer Initiative

Nov 4, 2026
Proactive Equities Team

Noxopharm (ASX: NOX) has locked in a $1.5 million placement and launched a $1.0 million share plan to fund its lupus skin study, FDA-guided Phase II preparation and cancer research, with convertible notes proposed to convert into shares.

FortifAI (ASX: FTI)

FortifAI (ASX: FTI): NOL8 Version 2.0 Release Marks Shift Towards Commercialisation

Nov 4, 2026
Proactive Equities Team

FortifAI (ASX: FTI) has released NOL8 Version 2.0 ahead of schedule, advancing its AI data infrastructure commercialisation strategy through independent performance testing, leadership appointments and preparations for enterprise customer adoption.

...

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics
Videos

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

12345...88
Page 1 of 88